Boehringer Ingelheim GmbH terminated its second metabolic dysfunction-associated steatohepatitis (MASH) alliance on March 6, ending an $870 million license agreement inked with Yuhan Corp. for dual ...

Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...

On the 7th, Yuhan Corporation announced that it received a notice of technology return for the new drug candidate 'BI3006337(YH25724)' that it had exported to the global pharmaceutical company ...

Some companies claim that taking beneficial bacteria can reduce the desire for sugar. But the evidence comes from mice, not people.

The number one unmet need is that we don't have a good handle on who's at risk, because patients generally don't have too ...

Survodutide also achieved ALT reduction of 65% after 1 year. Second, the FGF21 injectables (Pegozafermin and Efruxifermin), which in my view lag behind the GLP-1 class due to weaker ALT reduction ...

Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of ...

In a subgroup of patients with baseline and week 96 biopsies who were not taking GLP-1 at baseline (n=97), 45 ... biological activity profile of native FGF21, EFX is designed to offer convenient ...

In a subgroup of patients with baseline and week 96 biopsies who were not taking GLP-1 at baseline (n=97), 45 ... biological activity profile of native FGF21, EFX is designed to offer convenient ...

Q4 2024 Earnings Call Transcript February 27, 2025 Altimmune, Inc. beats earnings expectations. Reported EPS is $-0.33, ...

Turning our attention to the 2 additional indications, we believe these are areas of significant unmet medical need for which the balanced GLP-1 glucagon dual receptor agonism pemvidutide provides ...